How Does Miebo Work? Mechanism of Action Explained in Plain English

Miebo (perfluorohexyloctane) is unlike any other prescription dry eye drop. While most dry eye treatments work by reducing inflammation to help your eyes produce more tears, Miebo takes a completely different approach — it physically prevents your existing tears from evaporating. Here's how that works, explained without jargon.

First: Why Do Tears Evaporate?

Your tear film has three layers:

1. The lipid (oil) layer — the outermost layer, produced by the meibomian glands in your eyelids. This oil layer acts as a seal to prevent the water beneath it from evaporating.
2. The aqueous (water) layer — the thick middle layer produced by the lacrimal glands, which provides hydration and oxygen to the cornea.
3. The mucin layer — the innermost layer, produced by goblet cells in the conjunctiva, which helps the tear film adhere to the corneal surface.

In about 9 out of 10 people with dry eye, the lipid layer is deficient or dysfunctional — often due to meibomian gland dysfunction (MGD). When the oil layer is thin or unstable, the aqueous tear film beneath it evaporates rapidly. This leads to a cycle of corneal surface damage, inflammation, and worsening symptoms.

What Is Perfluorohexyloctane?

Perfluorohexyloctane (F6H8) is a semifluorinated alkane — a type of molecule that has both a fluorinated (fluorine-containing) and a hydrocarbon segment. These unique molecular properties give perfluorohexyloctane two important characteristics:

• It is water-free: The entire bottle contains 100% perfluorohexyloctane — there is no water. This means no preservatives are needed, since water-free environments don't support bacterial growth.
• It spreads instantly: Because of its very low surface tension, perfluorohexyloctane rapidly spreads across the ocular surface when instilled, covering it evenly and efficiently.

How Does Miebo Actually Work on the Eye?

When you instill a drop of Miebo, the perfluorohexyloctane rapidly spreads across the ocular surface and migrates to the air-liquid interface of the tear film — that is, the outermost surface where the tear film meets the air.

At this interface, the perfluorohexyloctane molecules form a thin, orderly

monolayer — a single-molecule-thick film. This monolayer acts similarly to a healthy lipid layer, creating a physical barrier that slows the evaporation of the aqueous tear film beneath it.

In laboratory (in vitro) studies, perfluorohexyloctane was shown to significantly inhibit evaporation from an aqueous surface. The mechanism is essentially replacing what healthy meibomian gland secretion (meibum) does naturally — protecting your tears from evaporating too quickly.

Is Miebo Absorbed Into the Body?

Minimally. A pharmacokinetic study following topical ocular administration of Miebo found low systemic blood levels of perfluorohexyloctane. The molecule is not metabolized by human liver enzymes (not broken down by cytochrome P450 enzymes), which is one reason Miebo has essentially no known drug-drug interactions. The drug stays where it's applied — on the ocular surface.

What Does the Clinical Evidence Say?

Two pivotal Phase 3 randomized controlled trials — GOBI and MOJAVE — enrolled more than 1,200 patients with DED associated with meibomian gland dysfunction. Patients used Miebo four times daily for 57 days.

Results in both trials:

• Corneal fluorescein staining (sign): Statistically significant reduction in total corneal staining score vs. saline control at Day 57
• VAS eye dryness score (symptom): Statistically significant reduction vs. saline control at Day 57
• Onset of benefit: Symptomatic improvement observed as early as Day 15 in both studies
• Safety: No serious ocular adverse events; discontinuation due to adverse events was comparable to saline control (0.2% vs. 0.5%)

How Does This Compare to Other Dry Eye Treatments?

Most other prescription dry eye medications — Restasis (cyclosporine 0.05%), Cequa (cyclosporine 0.09%), Xiidra (lifitegrast 5%), and Vevye (cyclosporine 0.1%) — are anti-inflammatory immunomodulators. They target the inflammatory process that damages lacrimal gland function, gradually restoring natural tear production over weeks to months. They don't directly address evaporation.

Miebo is not anti-inflammatory. It doesn't modulate the immune system. Its entire effect is physical: creating a monolayer that slows evaporation. This is why it can be used alongside anti-inflammatory drops as a complementary therapy for patients with both evaporative and inflammatory dry eye components.

The Bottom Line

Miebo works by doing what healthy meibomian glands do: forming a thin protective oil layer on the surface of the tear film to prevent evaporation. It's simple in concept, first-in-class in execution, and backed by two large randomized controlled trials. For more on what Miebo treats and how to use it, see our guide: What Is Miebo?